CA-INSEEGO-CORP
Inseego Corp. (Nasdaq: INSG), a leader in 5G and intelligent IoT device-to-cloud solutions, today announced that its new Wavemaker PRO 5G indoor router has been certified for use in Europe, North America* and Australia, with additional regulatory certifications pending for other international markets. Designed specifically for enterprise customers, this router combines high-performance, multi-carrier 5G and Wi-Fi 6 connectivity with cloud software that simplifies device management, maximizes security and minimizes expenses for enterprise users.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210209005447/en/
“Our Wavemaker PRO 5G solutions are changing the way enterprise and SMB customers think about broadband access,” said Inseego President Ashish Sharma. “Whether they have remote branch offices needing faster primary communications, retail locations needing failover solutions, or a distributed workforce needing dependable and secure work-from-home access to their corporate network, the FG2000e router can deliver unmatched speed, throughput and reliability — along with software solutions that make it easy for IT organizations to deploy and manage their devices, protect their networks, and reap the benefits of a multi-carrier 5G managed WAN.”
Bringing 5G enterprise solutions to global markets
The Wavemaker PRO 5G indoor router FG2000e has now received industry certifications that make it commercially available for deployments in many global markets. It’s important to understand that different countries and regions require different types of regulatory and 3GPP certifications in order to operate 5G products on mobile networks. For example, GCF certification demonstrates that products conform with 3GPP standards and will be interoperable with mobile networks worldwide. CE certification means that solutions can be sold to service providers and enterprise customers in over 30 countries of the European Economic Area (EEA) and European Free Trade Association (EFTA). RCM certification verifies that electrical and wireless equipment can be sold in Australia. And FCC certification requires a rigorous process of testing before RF products can be sold and marketed in the U.S.
Having completed all of these certifications, the FG2000e router can now be sold to service providers and enterprise customers across all of these regions, including organizations that are deploying 5G private networks.
New global channel partners
In addition to partnering with service providers, Inseego is expanding its network of distributors, resellers and system integrators worldwide to create new channels to market, along with local market support for its new enterprise solutions. The FG2000e router and software provides local language support, including English, French, Italian, Spanish, German, Arabic and Japanese.
A multi-carrier 5G cloud managed WAN for ubiquitous broadband connectivity
The Wavemaker PRO 5G indoor router FG2000e provides high-performance 5G connectivity and 4G LTE fallback, with features such as:
- Unlocked, dual-SIM, multi-carrier firmware that provides flexibility and ultimate control of the network the router connects to, avoiding downtime and data usage overage charges
- Centralized cloud management through the Inseego Manage ™ cloud solution, which simplifies device configuration, installation, remote management, security and support, providing an excellent customer experience right “out of the box” and for the full product lifecycle
- Enterprise-grade security that includes WPA3 Wi-Fi security support, advanced encryption, Open VPN and IPsec VPN
- Added value with a robust pipeline of new features including WAN management, enterprise security, device management and vertical market applications.
The Wavemaker PRO 5G indoor router FG2000e can deliver gigabit-plus speeds (using sub-6 GHz 5G) that match or outperform typical cable and fiber optic speeds. The FG2000e is ideal for business offices, retail locations, medical facilities, campuses and remote job sites needing reliable, high-speed broadband access with features such as:
- A 5 Gbps ethernet port, additional LAN and WAN ports, and TS9 port for external antenna
- Wi-Fi 6 technology to support up to 128 Wi-Fi-enabled devices
- An RJ-11 port for optional Voice over LTE (VoLTE)
5G for private networks
According to IDC , the private LTE/5G equipment market will reach $5.7 Billion in 2024. “With more spectrum being made available for enterprise uses, coinciding with the arrival of commercial 5G, interest has grown toward using private LTE/5G solutions as a basis for connectivity across a multitude of mission-critical, industrial and traditional enterprise organizations.”
Inseego 5G: Fast, reliable and secure
Designed and developed in the U.S., Inseego 5G products deliver high speed and low latency with extensive cybersecurity, including WPA3 Wi-Fi security with advanced encryption, Open VPN, IPsec VPN, parental controls and more.
To learn more about Inseego 5G products and solutions go to inseego.com . For press and analyst inquires, please email press@inseego.com
* Pending carrier approval.
About Inseego Corp.
Inseego Corp. (Nasdaq: INSG) is an industry leader in smart device-to-cloud solutions that extend the 5G network edge, enabling broader 5G coverage, multi-gigabit data speeds, low latency and strong security to deliver highly reliable internet access. Our innovative mobile broadband, fixed wireless access (FWA) solutions, and software platform incorporate the most advanced technologies (including 5G, 4G LTE, Wi-Fi 6 and others) into a wide range of products that provide robust connectivity indoors, outdoors and in the harshest industrial environments.
Designed and developed in the USA, Inseego products and SaaS solutions build on the company’s patented technologies to provide the highest quality wireless connectivity for service providers, enterprises, and government entities worldwide. www.inseego.com #Putting5GtoWork
©2021 Inseego Corp. All rights reserved. The Inseego name and logo are registered trademarks, and the Wavemaker and Inseego Manage names are trademarks of Inseego Corp. Other Company, product or service names mentioned herein are the trademarks of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210209005447/en/
Link:
Social Media:
https://www.facebook.com/Inseego/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HELUS Pharma Propels Therapeutic Innovation in Mental Health and Commences Trading on Nasdaq5.1.2026 13:30:00 CET | Press release
Helus Pharma builds on the strong foundation originally created as Cybin Inc., reflecting the Company’s ongoing transformation to a commercial stage pharmaceutical company Helus Pharma commences trading on Nasdaq Global Market (“Nasdaq”) and on Cboe Canada under ticker symbol: HELP Helus Pharma continues to progress its portfolio of novel serotonergic agonists (“NSAs”), with the goal of developing treatments designed to redefine mental health care, including HLP004 for the treatment of generalized anxiety disorder, with Phase 2 topline data readout expected in Q1 2026 Preparations in progress for the commercialization of HLP003, Helus Pharma’s NSA in Phase 3 clinical development, which has been granted Breakthrough Therapy Designation by the FDA for the adjunctive treatment of major depressive disorder This news release constitutes a “designated news release” for the purpose of the Company’s prospectus supplement dated December 30, 2025, to it short form base shelf prospectus dated Sep
Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for Diffuse Large B-Cell Lymphoma5.1.2026 13:30:00 CET | Press release
- Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP met its primary endpoint of progression-free survival (PFS) - Based on these results, Incyte plans to file a supplemental Biologics License Application (sBLA) for tafasitamab and lenalidomide in addition to R-CHOP in first-line diffuse large B-cell lymphoma (DLBCL) in the first half of 2026 Incyte (Nasdaq:INCY) today announced positive topline results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, and lenalidomide in addition to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) compared to R-CHOP alone as a first-line treatment for adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL) with an International Prognostic Index (IPI) score of three to five (3-5) for patients >60 years o
SBC Medical Accelerates Global Expansion with Strategic Investment and Alliance witha Leading U.S. MedSpa Platform OrangeTwist as Part of Broader Growth Strategy5.1.2026 13:00:00 CET | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to medical corporations and their clinics, today announced the completion of a strategic minority equity investment and the establishment of a structured collaboration framework with OrangeTwist, a leading U.S.-based MedSpa chain, alongside its longstanding institutional shareholders, Hildred Capital and Athyrium Capital. This transaction marks SBC Medical’s formal entry into the United States—a key global market for medical aesthetics—and represents a major milestone in the Company’s broader global expansion strategy. For more details, click here. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251210926005/en/ OrangeTwist Supporting 258 affiliated clinics worldwide and managing more than six million patient visits annually, SBC Medical has built one of the largest and
Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)5.1.2026 13:00:00 CET | Press release
Rusfertide Is a First-in-Class Investigational Hepcidin Mimetic That Targets Red Blood Cell Overproduction (Erythrocytosis) in Polycythemia Vera NDA Includes 52-Week Data from Phase 3 VERIFY Study, Which Met the Primary and All Four Key Secondary Endpoints, Showing Rusfertide Provided Durable and Sustained Hematocrit Control and Improved Pre-Specified Patient Reported Outcome Measures Data Underscore the Potential to Shift the Treatment Paradigm for PV Patients to Reduce the Burden of Frequent Phlebotomies and Meaningfully Improve Hematocrit Control Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics (Nasdaq: PTGX) (“Protagonist”) announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of rusfertide for the treatment of adults with polycythemia vera (PV). Rusfertide is an investigational first-in-class subcutaneously administered hepcidin mimetic peptide designed to regulate iron homeostasis and red blood cell product
Macnica Appoints Sebastien Dignard as CEO of Atlantic Region to Accelerate Global Component-to-Solutions and Vertical Strategy5.1.2026 12:00:00 CET | Press release
Macnica leader to strengthen cross-regional collaboration across the Americas and Europe Macnica Inc. today announced the promotion of Sebastien Dignard to chief executive officer of the company’s Atlantic region. In this role, Dignard will lead Macnica’s business across North America, Europe and South America, accelerating the company’s component-to-solutions strategy and strengthening cross-regional collaboration to deliver long-term value for customers and partners across key verticals. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260105529342/en/ Sebastien Dignard, CEO, Macnica Atlantic Region Dignard previously served as president of Macnica Americas for two years where he led the organization through a period of growth and transformation across semiconductors, imaging, networking and advanced technologies. Under his leadership, the company shifted from a focus on individual components to value-driven solutions, ecosy
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom